External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

External broker reports(aggregated public sources)

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

<ul><li>Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.</li><li>Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.</li><li>The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences - Growth to Improve

External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.</li><li>It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.</li><li>The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

<ul><li>In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%.</li><li>It surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.</li><li>The consolidated occupancies exhibited an impressive YoY improvement of 380bps, reaching 76.4%. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%.It surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.The consolidated occupancies exhibited an impressive YoY improvement of 380bps, reaching 76.4%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - Growth Led by Higher Occupancies and ARPOB

<ul><li> In Q1FY24, the company achieved a consolidated revenue of Rs 606 Cr, up 22.3%.</li><li>This performance surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.</li><li>The consolidated occupancies exhibited an impressive YoY improvement of 490bps, reaching 70.4%. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

 In Q1FY24, the company achieved a consolidated revenue of Rs 606 Cr, up 22.3%.This performance surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.The consolidated occupancies exhibited an impressive YoY improvement of 490bps, reaching 70.4%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - Margins Hit Due to Increase in Investment

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>With long-term structural factors supporting growth, healthcare services market is expected to have a low double-digit CAGR over the next five years.</li>
<li>Most of the leading hospitals are operating with high occupancies, which justifies their aggressive plans. Profitable revenue growth and low leverage support their expansion plans.</li>
<li>With expanding scale, the players are well positioned to report faster revenue growth and better margins in coming years than their respective historical figures.</li>
</ul>


With long-term structural factors supporting growth, healthcare services market is expected to have a low double-digit CAGR over the next five years.
Most of the leading hospitals are operating with high occupancies, which justifies their aggressive plans. Profitable revenue growth and low leverage support their expansion plans.
With expanding scale, the players are well positioned to report faster revenue growth and better margins in coming years than their respective historical figures.


Indian Hospitals on Expansion Spree; Sectoral Tailwinds and Financial Stability Provide Impetus

India

Krishna Institute of Medical Sciences Limited provides hospital services. The Hospital offers medical and surgical, renal and cardiac sciences, oncology, orthopaedics, organ transplantation, neurosciences, and other health care services. Krishna Institute of Medical Sciences serves patients in India.

Krishna Institute of Medical Sciences (KIMS IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

Krishna Institute of Medical Sciences - Growth to Improve

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences. We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical...

Prabhudas Lilladhar

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

Additionally, there was a 3.2%/-1.3% YoY/QoQ rise in ARPOB to Rs 30,741 during Q3FY24 which was below the industry levels.

Axis Direct

Krishna Institute Of Medical Sciences Ltd - Growth Led by Higher Occupancies and ARPOB

In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%. It surpassed our estimates and was primarily driven by enhancements in...

Axis Direct

Krishna Institute Of Medical Sciences Ltd - Margins Hit Due to Increase in Investment

In Q1FY24, the company achieved a consolidated revenue of Rs 606 Cr, up 22.3%. This performance surpassed our estimates and was primarily driven by...

Axis Direct

Indian Hospitals on Expansion Spree; Sectoral Tailwinds and Financial Stability Provide Impetus

Leading Indian hospitals are operating with high occupancies. Most of them chalked out major expansion plans over the next three years to benefit...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Krishna Institute of Medical Sciences - Growth to Improve

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences. We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical...

Prabhudas Lilladhar

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

Additionally, there was a 3.2%/-1.3% YoY/QoQ rise in ARPOB to Rs 30,741 during Q3FY24 which was below the industry levels.

Axis Direct

Krishna Institute Of Medical Sciences Ltd - Growth Led by Higher Occupancies and ARPOB

In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%. It surpassed our estimates and was primarily driven by enhancements in...

Axis Direct

Krishna Institute Of Medical Sciences Ltd - Margins Hit Due to Increase in Investment

In Q1FY24, the company achieved a consolidated revenue of Rs 606 Cr, up 22.3%. This performance surpassed our estimates and was primarily driven by...

Axis Direct

Indian Hospitals on Expansion Spree; Sectoral Tailwinds and Financial Stability Provide Impetus

​Leading Indian hospitals are operating with high occupancies. Most of them chalked out major expansion plans over the next three years to benefit...

Tina Banerjee

Leading Indian hospitals are operating with high occupancies. Most of them chalked out major expansion plans over the next three years to benefit...